Fawzi F Abu Rous, MD

Articles by Fawzi F Abu Rous, MD

FDA Approvals, Patient Selection, and SC Amivantamab

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

November 13th 2025

Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.

The Value of Subcutaneous Therapy for Patients

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

November 13th 2025

Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.

Sequencing Therapies and Using the Most Effective Options First

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

November 6th 2025

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Managing Adverse Events and Integrating Amivantamab Plus Lazertinib

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

November 6th 2025

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

CNS Penetration and Efficacy of Emerging Therapies

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

October 30th 2025

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Impact of Recent Approvals and Novel Mechanisms

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

October 30th 2025

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Overcoming Resistance Mechanisms and Addressing Unmet Needs

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

October 23rd 2025

Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.

Understanding EGFR Mutations and First-Line Treatment

ByJorge Garcia, PharmD, MS, MHA, MBA, FACHE,Joshua K. Sabari, MD,Amanda Cass, PharmD, BCPS, BCOP, Tammy McClellan, PharmD,Fawzi F Abu Rous, MD

October 23rd 2025

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.

Fawzi F Abu Rous, MD

Articles by Fawzi F Abu Rous, MD

FDA Approvals, Patient Selection, and SC Amivantamab

The Value of Subcutaneous Therapy for Patients

Sequencing Therapies and Using the Most Effective Options First

Managing Adverse Events and Integrating Amivantamab Plus Lazertinib

CNS Penetration and Efficacy of Emerging Therapies

Impact of Recent Approvals and Novel Mechanisms

Overcoming Resistance Mechanisms and Addressing Unmet Needs

Understanding EGFR Mutations and First-Line Treatment

Latest Updated Articles

Trending on AJMC

Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen

Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin

NIH F32 Grants Boost Early-Career Researchers’ Success

Nipocalimab Investigation Extends to Younger Patients: Jonathan Strober, MD

Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis